The FDA has approved a selegiline transdermal system (Emsam), the first patch for adults with major depressive disorder (MDD). Somerset Pharmaceuticals developed the drug, and Bristol-Myers Squibb will market it. Selegiline was approved in 1989 to treat Parkinson’s disease.
This drug is a monoamine oxidase inhibitor (MAOI). Consequently, the drug’s label will carry a black-box warning and a list of tyramine-containing foods and drinks that patients must avoid while using the patch.
The recommended starting dose is one 6-mg/24-hour patch administered once daily.